Brain & Behavior Research Foundation International Mental Health Research Symposium Featuring Talks on Psychosis, Child and Adolescent Psychiatry, Mood Disorders and More
October 17, 2024 11:19 ET
|
Brain & Behavior Research Foundation
New York, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) International Mental Health Research Symposium will be held on Friday, October 25, 2024, at the...
Toward Brain-Based Prediction of Recovery: How Neuroimaging Can Help Combat the Substance-Use Epidemic
October 02, 2024 12:00 ET
|
Brain & Behavior Research Foundation
New York, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Toward Brain-Based Prediction of Recovery: How Neuroimaging Can Help...
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
October 02, 2024 09:20 ET
|
PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
Psychiatry Collaboration and Licensing Deals Agreements Report and Directory 2024: Upfront, Milestone, Royalties - Company A-Z, Therapy Focus and Technology Type
September 30, 2024 05:20 ET
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Psychiatry Collaboration and...
Beacon Behavioral Partners Expands to Pennsylvania with Partnership of Nexus Group
August 15, 2024 15:17 ET
|
Beacon Behavioral Partners
Beacon Behavioral Partners announces its first partnership in Pennsylvania with Pittsburgh-based outpatient mental health facility Nexus Group.
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
August 09, 2024 18:28 ET
|
Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Today's Webinar from the Brain & Behavior Research Foundation - Motivational Modulation of Cognitive Control in ADHD
July 09, 2024 09:41 ET
|
Brain & Behavior Research Foundation
New York, July 09, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Motivational Modulation of Cognitive Control in ADHD” today, July 9, 2024,...
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 09, 2024 07:00 ET
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
July 01, 2024 04:30 ET
|
Nexstim Oyj
Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received...